Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Biotechnology

Healthcare
$536.45 -1.40%

-$6.43 today

Market cap
$136.01B
Beta
0.31
P/E (TTM)
26.5
EPS (TTM)
$17.07
52W Low $362.50High $507.92

Volume 1.29M

Average 1.26M

VRTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $1.1B rose 6.5% year over year, behind the +21.1% change in trailing-twelve-month net income. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Net income amounted to 32.7% of revenue in FY2025, up 27.9 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 21 analysts of $4.62B (+16.7%) for the fiscal year ending Dec 2026, a slowdown from the +838.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.1B+6.6% QoQ
Last fiscal yearDec 2025
$3.95B+838.1% YoY
LTMJun 2026
$4.41B+21.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.5%+13.5%+7.0 pp
1 year+838.1%+16.7%-821.3 pp
3-year CAGR+6.0%+15.1%+9.1 pp
5-year CAGR+17.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
3.95B USD
Year-over-year change
+838.1%
4-year CAGR
+14.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VRTX compares with its peers on the latest reported figures

  • VRTX's LTM Jun 2026 net income of $4.41B is the 2nd largest of the 11 companies compared; the peer median is $270.78M.
  • Its year-over-year change of +21.1% is the 5th highest of 11, against a peer median of +3.0%.
  • Net income amounts to 34.9% of revenue for VRTX, versus a peer median of 55.8%.
VRTX Competitors Peer median
Net Income for VRTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$27.6B +3808.4%+35.1%2.7%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$4.41B +21.1%+6.0%34.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$807.99M +353.2%—16.8%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$695.45M -11.4%+14.4%97.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$608.92M +10.8%-6.7%91.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M +113.1%+12.2%56.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M -4.8%+3.1%757.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026$456.14M -6.6%-3.6%1812.1%
BEAMBeam Therapeutics Inc.LTM Jun 2026$85.43M -78.6%-34.8%54.7%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.06M +126.2%+0.5%3.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$38.38M -106.1%—3.8%
Peer median (excluding VRTX) $270.78M+3.0%+1.8%55.8%

Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.34B3.32B3.62B(535.6M)3.95B
Depreciation & Amortization125.6M148.3M181.3M207.2M209.8M
Deferred Income Tax(154.6M)(275.9M)(536.5M)(348.8M)(510.8M)
Stock-Based Compensation441.4M491.3M581.2M698.5M685.9M
Change in Working Capital(105.2M)340.8M(265.7M)(514.8M)(1.2B)
Accounts Receivables(274.7M)(358.6M)(84.1M)(99.3M)(347.3M)
Inventory(92.8M)(136.4M)(322.9M)(517.3M)(524.2M)
Accounts Payables31.9M120.8M48.7M49.5M36.8M
Other Working Capital230.4M715M92.6M52.3M(364.4M)
Other Non-Cash Items(5.8M)103.4M(42.6M)900K492.4M
Operating Cash Flow2.64B4.13B3.54B(492.6M)3.63B
Capital Expenditures(235M)(204.7M)(258.4M)(297.7M)(437.6M)
Acquisitions (Net)77M(295.9M)000
Purchases of Investments(605.2M)(692.7M)(3.79B)(7.7B)(6.4B)
Sales of Investments499.3M920M934.2M4.47B5.91B
Other Investing Activities(77M)(47.8M)(89M)(241.7M)(24.7M)
Investing Cash Flow(340.9M)(321.1M)(3.14B)(3.77B)(945.4M)
Debt Repayment(18.7M)(85.5M)(44.9M)(33.6M)(5.4M)
Common Stock Issued102M186.3M134.6M114.6M127.7M
Common Stock Repurchased(1.43B)(172M)(427.6M)(1.18B)(2.02B)
Dividends Paid00000
Other Financing Activities(130.2M)3.5M(224.3M)(398.8M)(366.2M)
Financing Cash Flow(1.48B)(67.7M)(562.2M)(1.49B)(2.26B)
Effect of Forex Changes(13.4M)(29.2M)26.9M(42.6M)90.9M
Net Change in Cash811.2M3.71B(139.7M)(5.8B)515.6M
Free Cash Flow2.41B3.93B3.28B(790.3M)3.19B

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Intrinsic Alpha fair value

Locked

Current Price

$536.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.